Baxter Healthcare

1.1 Employee headcount trend

The headcount trajectory is not an organic-attrition story. The decline from roughly 60,000 to roughly 38,000 between FY2023 and FY2024 reflects the divestiture of BioPharma Solutions (closed September 2023) and the reclassification and subsequent sale of the Kidney Care business (closed 31 January 2025), rather than a workforce reduction programme. The much smaller step down from approximately 38,000 to 37,500 in FY2025 is where the genuine restructuring effect — the elimination of managerial layers described in the FY2025 10-K — begins to appear. FY2024 headcount is stated as approximate because Baxter's disclosure basis shifted mid-transition; the FY2025 figure is stated by the company "after giving effect to the Kidney Care sale."

1.2 Positioning statement (150 words)

Baxter International is a scale medical-products manufacturer whose defining characteristic is essentiality rather than novelty. Its portfolio — sterile IV solutions, infusion pumps and administration sets, parenteral nutrition, inhaled anesthetics, generic injectables, surgical hemostats and sealants, hospital smart beds, patient monitoring and respiratory devices — sits in the operational plumbing of acute care, where products are consumed continuously, specified by protocol, and purchased through GPO and IDN contracts rather than chosen by individual clinicians. That confers durable volume and formidable switching friction, but it also caps pricing power and exposes the company to hospital cost containment. Following the 2023 sale of BioPharma Solutions and the January 2025 sale of Kidney Care to Carlyle, Baxter is materially smaller, less diversified and considerably more levered than it was in 2021. Under CEO Andrew Hider, appointed in August 2025, the company is executing a deleveraging-and-operational-discipline programme rather than a growth strategy.

2.1 The company's own description

The FY2025 Form 10-K opens with a deliberately concrete self-description: Baxter, through its subsidiaries, provides a broad portfolio of essential healthcare products, including sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices. The company states that these products are used by hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers and patients at home under physician supervision, and that its global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries.

Management's stated mission is "to save and sustain lives" and its stated vision is "to redefine healthcare delivery." The FY2025 10-K frames the business strategy around five pillars: Innovation (organic and inorganic, focused on "connected care" and "core therapy" offerings); Portfolio Optimization (active assessment of strategic fit of businesses and geographies); Operational Simplification (the operating model implemented in Q3 2023 and further decentralised under Hider); Operational Excellence (automation, digitisation, and from October 2025 the "Baxter Growth and Performance System," a continuous-improvement and management-by-objectives business system); and Maintaining Disciplined and Balanced Capital Allocation.

2.2 Independent characterisation

Baxter is best understood as three distinct economic businesses that have been assembled under one roof and are currently being re-sorted:

(a) A high-volume, low-margin sterile fluids and infusion consumables business. IV solutions, administration sets, premixed drugs and parenteral nutrition are commodity-adjacent products sold under multi-year GPO contracts that explicitly limit Baxter's ability to raise prices. Economics are driven by manufacturing scale, plant utilisation, resin and freight costs, and freight-intensive logistics. This is the largest revenue block and the most exposed to input-cost inflation — the FY2025 10-K observes that because of the nature of its products and the geographic locations of its manufacturing, storage and distribution facilities, Baxter may be more susceptible to freight cost increases and other supply chain challenges than certain industry peers.

(b) A capital-equipment and installed-base business. Infusion pumps, smart beds, patient monitors, operating room integration systems and surgical tables are sold as capital purchases (or rentals) that seed a long tail of disposables, software subscriptions, service contracts and replacement cycles. This is where Baxter's "connected care" thesis lives, and it is the part of the portfolio acquired principally through Hillrom in 2021. It is higher-margin than fluids but more cyclical, because hospital capital budgets flex with health-system operating margins.

(c) A generic injectables and inhaled anesthetics business. This is a pharmaceutical business with pharmaceutical economics: regulatory approval barriers, periodic supply shortages that create windfalls, and structural price erosion in the absence of shortage. Within it, drug compounding — which is essentially 100% international, generating $1,141 million in FY2025 with zero U.S. revenue — is a service business, not a product business, and has been the fastest-growing division in the portfolio.

2.3 Revenue model and mix

Baxter does not disaggregate revenue into product, service and subscription buckets in its segment note. The practical composition is: predominantly product sales recognised at a point in time (Baxter's revenue policy states that most of its performance obligations are satisfied at a point in time); a smaller stream of rental and service revenue attached to the Hillrom-derived capital equipment; and a modest software/subscription element within Care & Connectivity Solutions (nurse-call, clinical communication, pump interoperability). Global payment terms are typically 30–90 days.

One revenue line deserves particular attention because it distorts headline growth: "Other." This category, which is not allocated to a reportable segment, jumped from $67 million in FY2024 to $381 million in FY2025 — a 469% increase. Almost all of that is sales to Vantive under the Kidney Care Manufacturing and Supply Agreement (MSA) entered into at the January 2025 closing. It is transfer-pricing revenue on products Baxter continues to make for its former subsidiary, it carries low margin, and management explicitly excludes it from "operational" and "organic" growth. Of Baxter's reported 6% FY2025 revenue growth, three percentage points were the Kidney Care MSA.

2.4 Value chain position, customers and end-markets

Baxter is a manufacturer that sells both directly and through intermediaries. It maintains its own direct sales force and also sells to and through independent distributors, drug wholesalers acting as sales agents, and specialty pharmacy and alternate-site providers. In the United States, third parties such as Cardinal Health, Inc. and Medline Inc. warehouse and ship a significant portion of Baxter's products through their distribution centres — a meaningful concentration point in the distribution chain.

The decisive commercial relationship, however, is with group purchasing organizations (GPOs) and integrated delivery networks (IDNs). Baxter holds purchasing agreements with several major U.S. GPOs, subject to periodic renewal. The 10-K risk factors are candid about the consequences: participation "often requires increased discounting or restrictions on our ability to raise prices," and failure to be awarded these agreements "might result in a reduction of sales to the member hospitals." Several of these agreements contain failure-to-supply clauses with remedies including limited termination rights — a clause type that became live during the Hurricane Helene disruption. Baxter also notes a trend of individual GPO members negotiating directly with manufacturers and demanding most-favoured-nation clauses.

End-markets served: acute-care hospitals and health systems (the dominant channel); ambulatory surgery centres; nursing homes and rehabilitation facilities; physician offices and clinics; home care under physician supervision; kidney dialysis centres (now largely as a supplier to Vantive rather than a direct participant); and government/national tender purchasers, particularly outside the United States, where an increasing number of countries run price-driven national or regional tenders.

10.1 Stated strategy — themes from the FY2025 Form 10-K

Management's own framing, in the order presented in Item 1:

1. Innovation. "Our innovation strategy, which encompasses both organic and inorganic initiatives over the longer term, is focused on accelerating our sales growth through the introduction of new customer centric connected care and core therapy offerings." Connected care is defined as devices or software that can digitally connect, communicate and/or analyse data. Core therapy is defined as pharmaceuticals and consumable medical products addressing essential needs across the continuum of care. The stated prioritisation is toward "markets with higher growth rates."
2. Portfolio Optimization. "Active portfolio management in the interest of maximizing value for Baxter stockholders," with regular assessment of the strategic fit of both businesses and geographies. Explicitly contemplates further market exits.
3. Operational Simplification. The Q3 2023 operating model, extended under Hider through "the elimination of managerial layers that are intended to simplify our organization, accelerate innovation, bring us closer to our customers and improve performance."
4. Operational Excellence. Automation and digitisation, including "our thoughtful exploration of artificial intelligence initiatives," and from October 2025 the Baxter Growth and Performance System (GPS) — described as "our high performance business system grounded in continuous improvement and management by objectives."
5. Maintaining Disciplined and Balanced Capital Allocation. Three named priorities: debt repayment to support deleveraging commitments; active portfolio management including further divestitures and market exits; and returning capital through dividends "and eventually share repurchases."

Hider's own framing on the Q4 2025 call was more pointed: a new operating model "designed to simplify our organization, accelerate innovation and improve performance," which "further decentralize[s] the business and embed[s] critical functional roles directly within each division," with the explicit objective of helping Baxter "improve our say-do ratio and execute more consistently."

10.2 Announced initiatives, last 24 months

10.3 Medium-term financial targets and guidance

Note that even the raised FY2026 EPS guidance midpoint of $2.05 sits below FY2025 actual adjusted EPS of $2.27. Management is guiding to a year of earnings decline.

The following catalogue is assembled from the FY2025 10-K product descriptions, earnings-release commentary, FDA recall notices, and company product communications. Baxter does not publish a complete SKU-level catalogue in its filings; brand lists below are therefore representative of the major named franchises rather than exhaustive, and pricing is not disclosed for any product line. Where a brand's current status could not be confirmed from a 2025–2026 source, it is flagged.

5.1 Medical Products & Therapies — Infusion Therapies & Technologies / Platforms

Sterile IV solutions. The core franchise: 0.9% sodium chloride, dextrose solutions, lactated Ringer's and Ringer's solutions, sterile water for injection, and irrigation solutions, supplied predominantly in flexible plastic containers under the VIAFLEX (Americas) and VIAFLO (international) container brands, with the non-PVC AVIVA container line for drugs sensitive to plasticisers. Target customers: hospital pharmacies, IDNs, national tender purchasers. Manufacture is concentrated in a small number of very large plants, chiefly North Cove (Marion, North Carolina), with additional large-volume capability in Mexico and Spain. Pricing: GPO-contracted, multi-year, with contractual limits on increases. Revenue significance: the largest single product family in the company, and the one whose FY2025 comparison was flattered by a weak, hurricane-affected FY2024 base.

Premixed and ready-to-use drug delivery. The GALAXY container system permits pre-mixed frozen or ready-to-use drug presentations, eliminating hospital-pharmacy admixture steps. Named products include NEXTERONE (premixed amiodarone HCl in Galaxy — the only premixed presentation of the drug), BREVIBLOC (esmolol HCl, ultra-short-acting beta blocker, in premixed bag and vial presentations), and MYXREDLIN (insulin human in 0.9% sodium chloride injection — the first and, for a period, only ready-to-use insulin presentation for IV infusion). MINI-BAG Plus provides a vial-to-bag closed reconstitution container. Target customer: hospital pharmacy, with the value proposition being medication-error reduction and pharmacy labour savings. This sub-franchise is where the post-Helene fluid-conservation demand reset has bitten hardest.

Infusion systems and devices. Three platforms:

• SPECTRUM IQ large volume infusion pump with Dose IQ Safety Software — the mature, installed-base platform, and currently Baxter's only fully available LVP in the U.S. and Canada. Supports bi-directional EMR interoperability; real-world data on more than one million infusions, developed with the University of Texas Medical Branch, was presented at the ASHP 2025 Midyear Clinical Meeting demonstrating patient-safety, productivity and programming-compliance benefits from EMR integration.
• NOVUM IQ Large Volume Pump (Novum LVP) — the next-generation platform, product code 40700BAXUS. Currently subject to a voluntary ship and installation hold in the U.S. and Canada except for medical necessity, in place since July 2025, following Class I recalls. Management expects no meaningful Novum LVP sales while the hold is in effect and describes release timing as uncertain.
• NOVUM IQ Syringe Pump (Novum IQ SP) — the companion syringe platform, also subject to a Class I correction in August 2025 for software anomalies producing a blank run screen and, on the SP, a false motor-movement system error.
• Administration sets and accessories — CLEARLINK and INTERLINK needle-free IV access systems and a broad set portfolio. These are the recurring-revenue tail behind the pump installed base and, commercially, the reason the pump hold matters far beyond pump revenue itself.

Parenteral nutrition. CLINIMIX and CLINIMIX E (amino acid in dextrose, with and without electrolytes), CLINOLIPID (lipid injectable emulsion), PERIKABIVEN / OLIMEL / NUMETA multi-chamber bag presentations in international markets (regional availability varies), and EXACTAMIX / EXACTAMIX Pro automated pharmacy compounders — the hardware inherited from the 2011 Baxa acquisition that allows hospital pharmacies to compound patient-specific nutrition admixtures. Target customers: hospital pharmacy, NICU and critical-care units, home infusion.

Inhaled anesthetics and generic injectables (from Q2 2026 reported within ITP). SUPRANE (desflurane, USP) plus sevoflurane and isoflurane presentations; a broad generic injectable portfolio spanning anti-infectives, analgesia, cardiovascular and critical-care molecules. Target customer: hospital pharmacy and anesthesia departments. Economics: shortage-driven volatility on the upside, structural price erosion on the downside. FY2025 revenue for Injectables & Anesthesia was $1,352 million, down 2%.

Drug compounding services. Outsourced sterile compounding delivered from Baxter facilities, sold entirely outside the United States — FY2025 revenue of $1,141 million with zero U.S. revenue, up 10% reported and 9% operational. This is the single fastest-growing line of scale in the company and the least discussed by management.

5.2 Medical Products & Therapies — Advanced Surgery

The highest-growth, highest-quality franchise in the portfolio: FY2025 revenue of $1,198 million, up 9% reported and 8% operational, accelerating to 13% reported and 11% organic in H1 2026 and 12% in Q2 2026 alone.

• TISSEEL — fibrin sealant (human), the flagship adjunctive hemostat and sealant, available in frozen, pre-filled syringe and lyophilised presentations, with spray and drip applicators.
• ARTISS — slow-setting fibrin sealant for tissue adherence in plastic and reconstructive surgery and burn graft fixation. A next-generation spray presentation for large-area burn and reconstructive surgery was launched in late 2025.
• FLOSEAL — flowable gelatin-thrombin hemostatic matrix, the volume workhorse for diffuse bleeding in cardiac, spinal, ENT and general surgery.
• HEMOPATCH — sealing hemostat patch (collagen-based with NHS-PEG coating) for parenchymal and vascular applications.
• PERICLOT — absorbable polysaccharide hemostatic powder.
• COSEAL — synthetic PEG-based surgical sealant for vascular anastomoses.
• SEPRAFILM — bioresorbable adhesion barrier, acquired from Sanofi in 2020, used in abdominal and pelvic surgery.
• ACTIFUSE — silicate-substituted calcium phosphate bone graft substitute.
• ALTIPLAST / ALTIPLEX — gelatin-based hemostats (availability by region; current status not separately confirmed in 2025–26 disclosure).

Target customers: hospital operating rooms and ambulatory surgery centres; purchasing typically via surgeon preference within GPO-negotiated bands, which is why this franchise carries better pricing than the fluids business.

5.3 Healthcare Systems & Technologies — Care & Connectivity Solutions

FY2025 revenue $1,911 million, up 5% reported / 4% operational; $1,372 million U.S. and $539 million international — the most U.S.-weighted division in the company.

Smart beds, surfaces and patient handling (Hillrom heritage):

• CENTRELLA Smart+ Bed — the flagship med-surg smart bed with integrated bed-exit, weight and skin-integrity monitoring.
• PROGRESSA+ Bed System — pulmonary and progressive-mobility bed for ICU.
• ENVELLA Air Fluidized Therapy Bed — for complex wound and burn management.
• COMPELLA Bariatric Bed System.
• AFFINITY 4 Birthing Bed — labour, delivery and recovery.
• VERSACARE / EXCEL CARE — legacy med-surg and bariatric platforms.
• DYNAMO SERIES smart stretcher — announced at the J.P. Morgan Healthcare Conference in January 2026 for U.S. launch, designed to reduce patient transfers and simplify positioning across emergency, perioperative and transport settings. The most significant new HST product in the current cycle.
• LIKO patient lifts and slings — safe patient handling.
• Therapeutic support surfaces and mattress replacement systems.

Clinical communication and workflow:

• VOALTE — mobile clinical communication platform (Voalte Nurse, Voalte Mobile), connecting nurses, physicians and alarm systems on smartphones.
• NaviCare / Hillrom Care Communications — nurse call, staff and asset locating, and clinical workflow software. This, together with pump and bed connectivity into hospital EMRs, is the substance behind the "connected care" positioning.

Advanced surgical equipment (Trumpf Medical and Allen Medical heritage):

• TruSystem operating tables, including hybrid and robotic-compatible configurations.
• TruLight surgical lighting.
• HELION Integration System — operating room video routing, documentation and integration.
• ALLEN MEDICAL precision positioning — Allen Advance Table for spinal surgery, Hug-U-Vac positioners, Bow Frame, and associated accessories.

5.4 Healthcare Systems & Technologies — Front Line Care

FY2025 revenue $1,160 million, up 2%; $871 million U.S. and $289 million international. This is the division whose goodwill was impaired by $425 million in FY2024 and a further $485 million in FY2025 — cumulative impairments approaching a billion dollars against a reporting unit generating little over a billion dollars of annual revenue. It is the clearest single admission that the Hillrom acquisition price was not recovered.

• WELCH ALLYN Connex Spot Monitor and Connex Vital Signs Monitor — spot-check and continuous vital signs.
• WELCH ALLYN CONNEX 360 Vital Signs Monitor — launched in Q4 2025 and specifically credited by management with driving Front Line Care growth in the quarter; the division's principal new product.
• Welch Allyn physical assessment — otoscopes, ophthalmoscopes, diagnostic sets, examination lighting (Green Series), and blood pressure instrumentation.
• Welch Allyn Spot Vision Screener and RetinaVue retinal imaging — point-of-care ophthalmic screening for primary care.
• Braun ThermoScan PRO professional thermometry.
• Cardiology and diagnostic cardiology (Mortara heritage): ELI series resting ECG (ELI 280, ELI 380), Q-Stress and X-Scribe cardiac stress testing, HScribe Holter analysis, Surveyor patient monitoring.
• BARDY DIAGNOSTICS CAM patch — ambulatory cardiac monitoring patch with P-wave-centric signal capture.
• Respiratory health: The Vest Airway Clearance System (high-frequency chest wall oscillation, used in cystic fibrosis, bronchiectasis and neuromuscular disease), VOLARA Oscillation and Lung Expansion system, METANEB system, and SYNCLARA cough assist.

5.5 Products no longer in the portfolio

For completeness, because their absence explains the revenue base: peritoneal dialysis, hemodialysis, continuous renal replacement therapy and organ support therapies (sold to Carlyle, January 2025, now Vantive Health LLC); BioPharma Solutions contract manufacturing and parenteral delivery services (sold to Advent/Warburg, September 2023); IV solutions in China (announced market exit, affecting MPT comparisons).

6.1 Basis note

FY2021 total-company results were reported before either divestiture and are not comparable to later years on any published basis. FY2022–FY2024 continuing-operations figures below are taken from the FY2024 10-K three-year income statement (which reflects both BPS and Kidney Care as discontinued operations); FY2025 from the Q4 2025 release and FY2025 10-K.

6.2 Total company net sales as originally reported at the time (memorandum only — do not use for growth analysis)

6.3 Income statement — continuing operations

6.4 Per-share and adjusted (non-GAAP) measures

6.5 Reconciliation of FY2025 special items (continuing operations, pre-tax operating income impact)

6.6 Balance sheet

Derived: total debt of $9,476 million at 31 December 2025 (the 10-K states approximately $9.48 billion of indebtedness outstanding); net debt of $7,510 million; working capital of $3,902 million; goodwill plus other intangibles of $9,298 million, equal to 46.4% of total assets and 152% of total equity. That last ratio is the single most important balance-sheet fact about Baxter: nearly half the asset base is purchase accounting, and a further impairment cycle would take equity down quickly.

6.7 Cash flow

H1 2026 free cash flow was $257 million, against $(144) million in H1 2025 — a $401 million swing, of which $181 million came in Q2 2026 alone. Q4 2025 free cash flow of $456 million exceeded the full-year figure of $438 million, confirming extreme second-half seasonality and, on management's own account, working-capital timing rather than a step change in cash generation.

6.8 Ratio analysis (all derived; Baxter does not publish these)

Methodology for the derived figures: adjusted EBITDA of approximately $1,972 million is calculated as adjusted operating income of $1,590 million plus estimated depreciation of approximately $382 million (total depreciation and amortisation less the $598 million of intangible amortisation already excluded from adjusted operating income). Baxter does not disclose a depreciation-only figure in the sources reviewed, so this is an estimate and the resulting leverage multiple should be treated as approximate. It is nonetheless consistent with S&P's published forecast of approximately 4.2x adjusted leverage in 2025 falling to 3.7x in 2026, and with management's stated target of approximately 3.0x by end-2026. ROIC uses adjusted operating income taxed at the 16.1% adjusted effective rate over invested capital of total debt plus equity less cash.

6.9 Commentary on trends, inflections and drivers

Revenue. The five-year revenue line is close to meaningless as reported, because the denominator changed twice. On a like-for-like continuing-operations basis, Baxter grew from $10,057 million in FY2022 to $11,244 million in FY2025 — a three-year CAGR of 3.8%, of which roughly a third is the Kidney Care MSA that did not exist before 2025. Underlying operational growth was 3% in FY2025 and is guided to approximately 2–3% organic in FY2026. This is a low-single-digit business, and management no longer pretends otherwise.

Gross margin — the central issue. Adjusted gross margin fell from 43.5% in FY2024 to 39.3% in FY2025, and reported gross margin from 37.5% to 30.1%. Q4 2025 was the acute episode: reported gross margin of 19.4% (against 34.8% a year earlier) and adjusted gross margin of 35.5% (against 44.5%). Management attributed the deterioration to unfavourable product mix, non-recurring inventory adjustments, and a higher effective tax rate. The Q2 2026 release adds a further explanation for 2026: the roll-through of higher-cost inventory produced at the end of 2025, and a reclassification of certain functional costs from SG&A into cost of sales — a presentational change that depresses gross margin without changing operating income, and which analysts must normalise for. Underlying drivers are structural: resin and electromechanical component costs, freight intensity, tariffs (explicitly stated to have adversely affected results), GPO pricing constraints, and adverse mix as Drug Compounding and IV solutions grow faster than Injectables and Advanced Surgery in absolute dollars.

Operating income. Adjusted operating margin has been remarkably stable at 13.9% and 14.1% in FY2024 and FY2025 — because a roughly 420 basis-point gross margin decline was offset almost exactly by a 270 basis-point reduction in adjusted SG&A (25.0% to 22.3%) and by the $189 million reduction in unallocated corporate costs. That is a cost-cut-funded margin defence, not operating leverage, and it has limited remaining runway.

Tax — the FY2025 shock. The FY2025 income tax expense of $395 million on a pre-tax loss of $505 million, producing an effective rate of negative 78.2%, is the single most arresting line in the statements. It is driven by increases in valuation allowances against U.S. deferred tax assets (a $330 million charge disclosed in Q4 alone), an increase in reserves for uncertain tax positions, and a step-up in Swiss valuation allowances, partially offset by a benefit from an internal reorganisation producing a capital loss. Recording a valuation allowance against U.S. DTAs is an accounting judgment that the company does not expect sufficient future U.S. taxable income to use them — a meaningful negative signal from management's own forecasting, independent of the cash impact. The adjusted effective rate of 16.1% is the operating reality; the GAAP rate is the accounting consequence of the last four years.

Balance sheet inflection. FY2025 is the year the deleveraging began in earnest. Total assets fell from $25,782 million to $20,055 million (chiefly the removal of $5,111 million of discontinued-operations assets). Total debt fell from approximately $13.1 billion to $9,476 million. Short-term debt went from $2,126 million to essentially nil. Financing outflows were $4,216 million. Baxter repaid $3.81 billion of legacy indebtedness in 2025 using Kidney Care proceeds, plus a further $2.00 billion refinanced with a new notes offering. Retained earnings fell $1,224 million, reflecting the net loss plus dividends.

Cash conversion is the weak point. Free cash flow of $438 million on adjusted net income of $1,136 million is a 39% conversion rate — poor for a mature medtech business, and the metric most deserving of scrutiny. Inventories of $2,232 million (104 days) rose 9% year over year on 6% sales growth, and management has acknowledged heightened inventory in certain parts of the business as a consequence of difficult demand forecasting post-Helene and post-Novum. Capital expenditure of $513 million (4.6% of sales) rose 15% year over year while R&D fell 12%, a mix that favours plant and quality systems over pipeline.

22.1 Management guidance

Medium-term commitments: net leverage of approximately 3.0x by the end of 2026; stranded costs from the Kidney Care sale fully eliminated by 2027; investment grade rating retained; no buybacks and highly selective M&A during deleveraging; dividend maintained at $0.01 per quarter with no commitment to increase.

22.2 Consensus expectations

The sell side is uniformly at Hold with a consensus price target of approximately $28 — roughly 3% above the 13 August 2026 price of $27.10. Price targets from BofA ($28), TD Cowen ($29) and Deutsche Bank ($27) cluster tightly. The implicit consensus view is that the Q2 2026 inflection is real enough to justify a higher price but not yet durable enough to justify an upgrade. Analysts had previously forecast FY2026 EPS around $2.69, well above the current guidance range, indicating that consensus estimates were reset downward substantially during 2025.

22.3 Bull case

1. The margin recovery is arithmetically large and mechanically identifiable. Adjusted gross margin fell from 43.5% to 39.3% between FY2024 and FY2025 on causes that are individually reversible: Hurricane Helene costs of $133 million, high-cost inventory produced in late 2025 rolling through 2026, tariffs (already partly refunded following the February 2026 Supreme Court ruling, worth $0.11 per share in Q2 2026 alone), and unfavourable mix from the Novum hold. Adjusted operating margin has already been held flat at approximately 14% through the worst of it. If even 200 basis points of gross margin return by 2027 on an $11.5 billion revenue base, that is roughly $230 million of operating income against a current adjusted base of $1,590 million — a 14% increase before any volume growth.

2. Deleveraging materially resets the equity. Net debt fell from $11,362 million to $7,510 million during FY2025. If Baxter reaches approximately 3.0x net leverage by end-2026 as targeted, roughly $1.5 billion of further debt reduction accrues directly to equity holders at a market capitalisation of $14 billion. The August 2026 tender for long-dated notes trading below par accelerates this and generates accounting gains. A restored balance sheet also removes the S&P downgrade overhang and reopens buybacks, dividend growth and bolt-on M&A from 2027.

3. The operating system is the right one for this asset. Hider's Danaher-and-ATS lineage applied to a company with a 118-day cash conversion cycle, 104 days of inventory, 39% free cash flow conversion and 14% operating margins is a genuine fit. Q2 2026 already showed growth in every segment and division in both geographies, free cash flow of $181 million, and a guidance raise — the first coherent quarter since the crisis began. GPS is a multi-year compounding mechanism, not a one-time cost programme.

22.4 Bear case

1. The core franchise is shrinking in its largest market and management says the cause is permanent. U.S. Infusion Therapies revenue fell 2% in FY2025 and 4% in H1 2026. The FY2025 10-K states that post-Helene clinical practices "appear to have reset demand levels in our IV solutions business" and hurt premix sales. This is a $4.1 billion franchise — over a third of company revenue — in structural decline in the United States, and no cost programme fixes a shrinking top line. Meanwhile the Novum LVP remains off the market with uncertain release timing, and S&P has explicitly flagged the risk of customers migrating to competing pumps on capital cycles that lock in for a decade.

2. The balance sheet is 46% intangibles and has been impaired three times in four years. Goodwill plus other intangibles of $9,298 million equals 152% of total equity of $6,102 million. The Front Line Care reporting unit has absorbed $910 million of goodwill impairment in two consecutive years and is still not growing. A third Front Line Care impairment, or a first impairment elsewhere in the Hillrom-derived asset base, would take equity down quickly at a company already one notch above high yield with a stable outlook conditioned on hitting a leverage target. The $330 million U.S. deferred tax asset valuation allowance is management's own signed statement that it does not expect enough U.S. taxable income to use those assets.

3. There is no finance leadership, and there is active securities litigation covering a four-year class period. Baxter will have had three CFOs and a vacant Chief Accounting Officer role within eighteen months. Simultaneously it faces class actions covering purchasers from 23 February 2022 through 29 October 2025, built on the gap between disclosing one serious injury in April 2025 and 79 serious injuries and two deaths in July 2025, plus ethylene oxide litigation in a jurisdiction that has produced very large verdicts against other defendants. The turnaround depends on one executive, roughly one year in, without a permanent CFO, while R&D has been cut 12% and the option package granted to retain him is underwater.

22.5 Catalysts and monitorables — next twelve months

22.6 Analyst verdict (300 words)

Baxter is a genuinely improving business inside a permanently smaller and structurally disadvantaged one, and both facts must be held simultaneously.

The improvement is real. Q2 2026 delivered growth in every segment, division and geography, free cash flow of $181 million, a guidance raise, and the first coherent quarter since the Novum crisis began. Debt fell by roughly $3.6 billion in 2025. Advanced Surgery is compounding at 12–13%. Adjusted operating margin held flat through a 420 basis point gross margin collapse — genuine cost discipline. The August 2026 tender retires long-dated paper below par. Andrew Hider's operating system is the correct toolkit for a company with 118 days of cash conversion cycle and 39% free cash flow conversion, and the improvement runway is wide precisely because the starting point is poor.

The structural problem is equally real. Baxter earns a 14.1% adjusted operating margin against BD at 25.0% and Stryker at 26.3%, grows organically at 2–3% against Stryker at 10%, and funds its deleveraging partly by cutting R&D — down 12% to 4.6% of sales. Its largest franchise is shrinking in its largest market for reasons management itself describes as a permanent demand reset. Its flagship next-generation pump has been off the U.S. market for over a year following Class I recalls associated with 79 serious injuries and two deaths. Forty-six percent of the balance sheet is purchase accounting that has been written down three times in four years. And it has no permanent CFO.

At approximately 13x guided FY2026 adjusted EPS and roughly 11x derived EV/adjusted EBITDA, the market is pricing a business that stabilises but does not re-rate to peer quality. That is the correct base case. The stock is a credible deleveraging and self-help trade with a defined catalyst path; it is not, on current evidence, a quality compounder, and the 91% spread in its 52-week trading range is an honest reflection of how wide the distribution of outcomes remains.

End of dossier. All figures are as of the dates stated. Items marked "not verified in this research pass" or "not publicly disclosed" should be sourced directly from Baxter's SEC filings, the 2026 proxy statement, the 2025 Sustainability Report, or the relevant rating agency before being relied upon.

Covering approximately February 2025 through August 2026.